GlassScriptPhysician profile
Safwan Jaalouk
NPI 1619977121
$16,475.76
in general payments reported to CMS, 2019-2025
25 companies · $698 in 2025
The $698 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,351 · 2020: $359 · 2021: $662 · 2022: $2,193 · 2023: $596 · 2024: $11K · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,540 · Food and Beverage: $2,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,539.55 |
| Food and Beverage | $2,371.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,288.77 | 2021-2025 | Corevalve Evolut R |
| Abiomed | $1,931.79 | 2019-2025 | Impella |
| Abbott Laboratories | $1,505.88 | 2019-2025 | Mitraclip, Triclip, Coroflow |
| Boston Scientific Corporation | $564.08 | 2019-2024 | Watchman Access System, Watchman Flx |
| Ge Healthcare | $227.74 | 2019-2020 | |
| Biotronik INC. | $131.39 | 2019 | |
| Edwards Lifesciences Corporation | $115.67 | 2023-2024 | Pascal |
| Amgen INC. | $90.20 | 2019-2020 | |
| Pfizer INC. | $88.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $85.11 | 2019 | |
| Cvrx, INC. | $70.56 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $61.55 | 2019-2022 | |
| Akcea Therapeutics, INC. | $58.49 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.54 | 2022-2025 | Lifevest |
| Medtronic Vascular, INC. | $42.75 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $39.64 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Cook Medical LLC | $29.15 | 2020-2025 | Rosen |
| Acist Medical Systems, INC. | $18.49 | 2025 | |
| Penumbra, INC. | $17.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.43 | 2025 | Eliquis |
| Chiesi USA, INC. | $11.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.64 | 2019 | |
| Amarin Pharma, INC. | $11.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safwan Jaalouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.